Company intelligence / Profile preview
Shanghai Thederma
Shanghai / Pudong, Shanghai Shi, Chinathederma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Shanghai Thederma is developing small molecule drugs targeting immune-mediated diseases. Its lead asset targets the aryl hydrocarbon receptor for seborrheic dermatitis and has reached Phase 2/3 clinical trials. Another program is in development for inflammatory bowel disease. At least one product appears to be approved or near approval as of June 2025.
- Therapeutic areas
- GastroenterologyDermatology
- Modalities
- Small moleculeChemical drugs
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Shanghai Thederma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Thederma.